Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy

The approval of monoclonal antibodies against programmed death-ligand 1 (PD-L1) and programmed cell death protein (PD1) has changed the landscape of cancer treatment. To date, many immune checkpoint inhibitors (ICIs) have been approved by the FDA for the treatment of metastatic cancer as well as loc...

Descripción completa

Detalles Bibliográficos
Autores principales: Strati, Areti, Economopoulou, Panagiota, Lianidou, Evi, Psyrri, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296703/
https://www.ncbi.nlm.nih.gov/pubmed/37371863
http://dx.doi.org/10.3390/biomedicines11061768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296703/
https://www.ncbi.nlm.nih.gov/pubmed/37371863
http://dx.doi.org/10.3390/biomedicines11061768

Ejemplares similares